文献速递前列腺癌

原发前列腺癌中高肿瘤内浆细胞含量定义了对免疫治疗潜在敏感的肿瘤亚群

High intratumoral plasma cells content in primary prostate cancer defines a subset of tumors with potential susceptibility to immune-based treatments.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2022-05-14

该研究回顾性分析三个独立队列超1300例前列腺肿瘤的分子谱,验证了基于表达特征的肿瘤内浆细胞含量签名,并发现高浆细胞含量与免疫治疗预测反应增加、雄激素剥夺治疗反应降低相关,低浆细胞肿瘤中过活化的主调控因子与根治性前列腺切除术后更短的无转移生存相关。

要点

  • 在高危原发前列腺癌中,高浆细胞含量肿瘤与免疫治疗预测反应增加和雄激素剥夺治疗反应降低相关。
  • 低浆细胞含量肿瘤中过活化的主调控因子与根治性前列腺切除术后更短的无转移生存相关。
  • 浆细胞活性标志物可能有助于未来免疫新辅助试验的靶向选择和患者富集。

核心结论

  • 浆细胞活性标志物可能用于优化临床试验的靶向和选择,并更好地理解局部治疗后高复发风险前列腺癌患者接受免疫治疗的潜力。

研究设计与样本

  • 对三个独立队列超过1300例前列腺肿瘤的分子谱进行回顾性分析。
  • 使用Wilcoxon秩和检验比较肿瘤内浆细胞含量高与低的肿瘤之间的分子通路。
  • 使用多变量Cox比例风险回归分析评估无转移生存。

主要发现

  • 在113例具有RNA表达数据和基于免疫组化的CD138+细胞(浆细胞标志物)数字图像定量的原发前列腺肿瘤中验证了肿瘤内浆细胞含量的表达签名。
  • 该签名显示,既往接受更多全身治疗的去势抵抗性肿瘤(n=101)含有更低的浆细胞含量。
  • 在高危原发前列腺癌中,高浆细胞含量肿瘤与免疫治疗预测反应增加和雄激素剥夺治疗反应降低相关。
  • 主调控因子分析识别出在浆细胞高肿瘤中上调的参与免疫(如SKAP1、IL-16和HCLS1)和B细胞活性(如VAV1、SP140和FLI-1)的转录因子。
  • 在浆细胞低肿瘤中过活化的主调控因子与根治性前列腺切除术后更短的无转移生存相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data on advanced prostate cancer (PCa) suggest more prior systemic therapies might reduce tumor immune responsiveness. In treatment-naïve primary PCa, recent work correlated intratumoral plasma cell content with enhanced tumor immune-responsiveness. We sought to identify features of localized PCa at a high risk of recurrence following local treatment with high plasma cell content to help focus future immune-based neoadjuvant trials. METHODS: We performed retrospective analyses of molecular profiles from three independent cohorts of over 1300 prostate tumors. We used Wilcoxon Rank Sum to compare molecular pathways between tumors with high and low intratumoral plasma cell content and multivariable Cox proportional hazards regression analyses to assess metastasis-free survival. RESULTS: We validated an expression-based signature for intratumoral plasma cell content in 113 primary prostate tumors with both RNA-expression data and digital image quantification of CD138+ cells (plasma cell marker) based on immunohistochemisty. The signature showed castration-resistant tumors (n = 101) with more prior systemic therapies contained lower plasma cell content. In high-grade primary PCa, tumors with high plasma cell content were associated with increased predicted response to immunotherapy and decreased response to androgen-deprivation therapy. Master regulator analyses identified upregulated transcription factors implicated in immune (e.g. SKAP1, IL-16, and HCLS1), and B-cell activity (e.g. VAV1, SP140, and FLI-1) in plasma cell-high tumors. Master regulators overactivated in tumors with low plasma cell content were associated with shorter metastasis-free survival following radical prostatectomy. CONCLUSIONS: Markers of plasma cell activity might be leveraged to augment clinical trial targeting and selection and better understand the potential for immune-based treatments in patients with PCa at a high risk of recurrence following local treatment.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Weiner AB, Yu CY, Kini M, et al. High intratumoral plasma cells content in primary prostate cancer defines a subset of tumors with potential susceptibility to immune-based treatments. Prostate Cancer Prostatic Dis. 2022. PMID: 35568781. doi:10.1038/s41391-022-00547-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。